Key facts
- It has raised $1.0M; the latest was Early Stage VC ($1.0M) in Dec 2025.
- Notable investors include 212, Arya Ventures, Simya.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Reprai
- ·The full record, as it builds
Funding rounds
No funding rounds for Reprai are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reprai
Developer of an AI-powered pharmaceutical promotion platform designed to support and automate promotional operations for pharmaceutical companies. The company's platform automates routine processes, provides real-time segmentation, and delivers tailored content to each audience by analyzing interactions with HCPs to continuously learn and improve, enabling businesses to handle the complexities of promotional operations and streamline the workflow.
- Sector
- Healthcare
- HQ
- Wilmington, DE, United States
- Founded
- 2024
- Employees
- 9
- Website
- reprai.com/
- Ownership
- Privately Held (backing)
Reprai doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reprai shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reprai in its N-PORT filings yet. We sweep new filings monthly.